tbuckley/cabot-search huggingface dataset:
Potentiation of Azidothymidine Cytotoxicity in Cisplatin-resistant Human Ovarian Carcinoma Cells
Authors: Kevin J. Scanlon, Tadao Funato, Babak Pezeshki, Takeshi Tone, Lawrence C. Sowers
Journal: Cancer Communications (1990)

The combination of cisplatin and AZT was synergistic in a subline (A2780DDP) of human ovarian carcinoma cells resistant to cisplatin, in contrast to the parental carcinoma cell line, A2780S. A2780DDP cells have elevated levels of enzymes necessary for DNA synthesis and repair. If A2780DDP cells respond to cisplatin with an increase in thymidine kinase activity, then AZT may chain terminate newly synthesized DNA. To test this hypothesis, a dual label [( 14C]-thymidine/[3H]-AZT) experiment was designed. A2780 cells were first incubated with [14C]-thymidine to label DNA and measure DNA degradation in response to cisplatin. These [14C]-thymidine labeled A2780 cells were then incubated for short intervals with [3H]-AZT to measure chain termination after cisplatin addition. A2780S cells responded to cisplatin with a modest increase in thymidine turnover and an increase in AZT incorporation. In contrast, A2780DDP cells initially responded to cisplatin treatment with a significant increase in thymidine turnover and a corresponding increase in [3H]-AZT incorporation. This was concomitantly associated with an increase in thymidine kinase mRNA within 2 hr after cisplatin treatment. Thus, the A2780DDP cells had the ability to rapidly turnover DNA, a property effectively exploited by the deoxythymidine analogue, AZT, utilizing the enhanced enzymes of the DNA synthesis and repair complex in A2780DDP cells.
Evaluation Of Circulating Cell-Free VDJ DNA As a Marker For Monitoring Patients With Multiple Myeloma (MM) During Treatment With Carfilzomib, Lenalidomide and Dexamethasone,
Authors: Roger Kurlander, Yixin LI, Maryalice Stetler-Stevenson, Constance Yuan, Neha Korde, Sham Mailankody, Mary Kwok, Elisabet E. Manasanch, Manisha Bhutani, Nishant Tageja, Dickran Kazandjian, Rene Costello, Yong Zhang, Adriana Zingone, Peter Wu, Marcia Mulquin, Diamond Zuchlinski, Irina Maric, Katherine R Calvo, Raul C. Braylan, Mark Roschewski, Ola Landgren
Journal: Blood (2013)
Trials of Zika vaccine are set to begin in North America
Authors: Owen Dyer
Journal: BMJ (2016)

The first potential vaccine against the Zika virus to be approved for testing in humans is set to begin phase I clinical trials in the United States.

The vaccine’s maker, Inovio, of Pennsylvania, is currently completing the paperwork to begin recruitment of 40 volunteers to participate in Philadelphia, Miami, and an undisclosed site in Canada.

The first vaccinations are expected within a few weeks, said Inovio’s president, Joseph Kim, and the first results by the year’s end. In animal trials the experimental vaccine, known as GLS-5700, elicited an immune response in mice, rabbits, and monkeys.

Other collaborators in the project include the University of Pennsylvania, the biomedical Wistar Institute in Philadelphia, and GeneOne Life Science, of …
The short-term association between asthma hospitalisations, ambient temperature, other meteorological factors and air pollutants in Hong Kong: a time-series study
Authors: Holly Ching-yu Lam, Albert Martin Li, Emily Ying-yang Chan, William Bernard Goggins
Journal: Thorax (2016)

Previous studies have found associations between meteorological variables and asthma hospitalisations but the nature of these associations has varied and few studies have been done in subtropical areas or evaluated effect modification by age.This study aimed to evaluate associations between asthma hospitalisations and meteorological factors and to assess effect modification of these associations by age and season in Hong Kong.Poisson generalised additive models combined with distributed lag nonlinear models and piecewise linear models were used to model associations between daily asthma hospitalisations from 2004 to 2011 and meteorological factors and air pollutants, adjusting for day of week, seasonality and trend. Subgroup analyses by age and season were performed.In the hot season, hospitalisations were lowest at 27°C, rose to a peak at 30°C, then plateaued between 30°C and 32°C. The cumulative relative risk for lags 0-3 days (RRlag0-3) for 30°C vs 27°C was 1.19 (95% CI 1.06 to 1.34). In the cold season, temperature was negatively associated with asthma hospitalisations. The cumulative RRlag0-3 for 12°C vs 25°C was 1.33 (95% CI 1.13 to 1.58). Adult admissions were most sensitive to temperatures in both seasons while admissions among children under 5 were least associated. Higher humidity and ozone levels in the hot season, and low humidity in the cold season were also associated with more asthma admissions.People with asthma should avoid exposure to adverse conditions by limiting outdoor activities during periods of extreme temperatures, combinations of high humidity and high temperature, and low humidity and low temperature, and high ozone levels.
On-Treatment Outcomes in Patients With Worsening Renal Function With Rivaroxaban Compared With Warfarin
Authors: Christopher B. Fordyce, Anne S. Hellkamp, Yuliya Lokhnygina, Samuel M. Lindner, Jonathan P. Piccini, Richard C. Becker, Scott D. Berkowitz, Günter Breithardt, Keith A. A. Fox, Kenneth W. Mahaffey, Christopher C. Nessel, Daniel E. Singer, Manesh R. Patel
Journal: Circulation (2016)

Background: Despite rapid clinical adoption of novel anticoagulants, it is unknown whether outcomes differ among patients with worsening renal function (WRF) taking these new drugs compared with warfarin. We aimed to determine whether the primary efficacy (stroke or systemic embolism) and safety (major bleeding and nonmajor clinically relevant bleeding) end points from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation trial) differed among participants with WRF taking rivaroxaban and those taking warfarin. Methods: After excluding patients without at least 1 follow-up creatinine measurement (n=1624), we included all remaining patients (n=12 612) randomly assigned to either rivaroxaban or dose-adjusted warfarin. On-treatment WRF (a decrease of &gt;20% from screening creatinine clearance measurement at any time point during the study) was evaluated as a time-dependent covariate in Cox proportional hazards models. Results: Baseline characteristics were generally similar between patients with stable renal function (n=9292) and WRF (n=3320). Rates of stroke or systemic embolism, myocardial infarction, and bleeding were also similar, but WRF patients experienced a higher incidence of vascular death versus stable renal function (2.21 versus 1.41 events per 100 patient-years; P =0.026). WRF patients who were randomized to receive rivaroxaban had a reduction in stroke or systemic embolism compared with those taking warfarin (1.54 versus 3.25 events per 100 patient-years) that was not seen in patients with stable renal function who were randomized to receive rivaroxaban ( P =0.050 for interaction). There was no difference in major or nonmajor clinically relevant bleeding among WRF patients randomized to warfarin versus rivaroxaban. Conclusions: Among patients with on-treatment WRF, rivaroxaban was associated with lower rates of stroke and systemic embolism compared with warfarin, without an increase in the composite bleeding end point. Clinical Trial Registration: URL: http://www.clinicaltrials.gov . Unique identifier: NCT00403767.
"THE MEDICAL TREATMENT OF GASTRIC ULCER"
Authors: J Bertrand, J M Jankowski
Journal: JAMA (1921)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Phase I study of the selective BRAF<sup>V600 </sup>inhibitor encorafenib (LGX818) combined with cetuximab and with or without the α-specific PI3K inhibitor BYL719 in patients with advanced <i>BRAF</i>-mutant colorectal cancer.
Authors: Robin Van Geel, Elena Elez, Johanna C. Bendell, Jason Edward Faris, Martijn P. J. K. Lolkema, Ferry Eskens, Anna Spreafico, Petr Kavan, Jean-Pierre Delord, Martin H. Schuler, Zev A. Wainberg, Yasuhide Yamada, Takayuki Yoshino, Tim Demuth, Emin Avsar, Arkendu Chatterjee, Peijuan Zhu, Rene Bernards, Josep Tabernero, Jan HM Schellens
Journal: Journal of Clinical Oncology (2014)

3514 Background: In contrast to BRAFV600 mutated (BRAFm) advanced melanoma, BRAFm colorectal carcinoma (CRC) does not respond to BRAF inhibitors due to strong feedback activation of the epidermal growth factor receptor (EGFR) upon BRAF inhibition. However, combining a BRAF and an EGFR inhibitor resulted in strong synergistic activity with complete inhibition of tumor growth in vitro and in vivo. The addition of a phosphatidylinositol 3-kinase (PI3K) inhibitor increased synergy. Methods: This is a phase I study evaluating safety, tolerability and anti-tumor activity of encorafenib (LGX818), a highly selective BRAF V600 inhibitor, the EGFR mAb cetuximab, ± the α-specificPI3K inhibitor BYL719 in patients (pts) with advanced BRAFm/KRAS wild-type CRC. Cohorts of pts were treated with escalating doses of oral encorafenib once daily in combination with IV cetuximab (400 mg/m2 loading dose, 250 mg/m2weekly) (dual arm), or with escalating doses of oral encorafenib and oral BYL719 once daily in combination with cetuximab (triple arm). Results: By November 08, 2013, 18 pts were enrolled across four dual combination dose levels: 100 (n = 2), 200 (n = 4), 400 (n = 9) and 450 mg (n = 3) encorafenib. Three pts were enrolled in the triple arm at 200 mg encorafenib, 100 mg BYL719 and cetuximab. Dose escalation has been completed in the dual arm where a phase 2 dose has been identified; dose finding is ongoing in the triple arm. In the dual arm, 2 dose-limiting toxicities, vomiting grade 3 (400 mg) and QTc prolongation grade 3 (450 mg), were observed, and fatigue (33%) and vomiting (28%) were the most frequently observed treatment-related adverse events. Three partial responses, including one in the triple arm, have been observed and prolonged disease stabilization was frequently achieved including two pts that have remained on treatment for one year. Decrease in carcinoembryonic antigen (CEA) has also been observed. Updated data from the triple arm will be presented. Conclusions: These results indicate that combination treatment of encorafenib and cetuximab ± BYL719 is well tolerated with promising antitumor activity in pts with advanced BRAFm CRC who failed standard treatment. Clinical trial information: NCT01719380.
US officials ban Theranos CEO from running laboratories for two years
Authors: Michael McCarthy
Journal: BMJ (2016)

US federal regulators have banned Elizabeth Holmes, the founder and chief executive officer of the biotechnology company Theranos, from operating blood testing laboratories for at least two years and have revoked the company’s laboratory certification, a company press release announced on 7 July.

The California based company’s executives had promised to revolutionize the blood testing industry with a technology that Theranos said would make it possible to run multiple …
Identification of Genes Abnormally Expressed in Both Human and Murine MLL-ELL and/or MLL-ENL Leukemia.
Authors: Zejuan Li, Miao Sun, Shuangli Mi, Roger T. Luo, Jingyue Bao, MeryBeth Neilly, Nimanthi Jayathilaka, Yanming Zhang, Deborah S. Johnson, Lili Wang, Catherine Lavau, Charles Tseng, Xiuqing Zhang, Jian Wang, Jun Yu, Huanming Yang, Michael J. Thirman, San Ming Wang, Janet D. Rowley, Jianjun Chen
Journal: Blood (2006)
Very low pressure irrigation is effective at reducing reoperation risk for open fracture wounds, study finds
Authors: Susan Mayor
Journal: BMJ (2015)

Very low pressure irrigation of open fractures is as effective at reducing the risk of reoperation for wound infection or inadequate healing as more costly high pressure irrigation, a study has shown. It also found that cleaning wounds with normal saline solution is better than irrigating with soap solution.

Effective management of open fractures requires thorough irrigation and debridement of the wound to remove debris and reduce the risk of infection. Wounds can be irrigated at low pressure—typically using a bulb syringe or using a fluid bag and giving set—or pulsed lavage devices can be …
Employment status and work-related difficulties in lung cancer survivors compared with general population.
Authors: Y. Kim, Y. Shim, J. Zo, Y. Yun
Journal: Journal of Clinical Oncology (2010)

e19596 Background: Although improved lung cancer survival is likely to result in increased lung cancer survivors, little was known about work situation among lung cancer survivors. The purpose of this study was to investigate employment status and work-related difficulties lung cancer survivors compared with the general population. Methods: We enrolled 917 lung cancer survivors from two hospitals 12 months after lung cancer surgery and 1,000 volunteers from the general population. Multivariate logistic regression was used to identify the factors associated with work situation. Results: Employment decreased from 69.6% to 38.7% after cancer treatment. The proportion of lung cancer survivors who remained working was significantly smaller relative to that of the general population (63.5%) [adjusted odds ratio (aOR) = 2.59; 95% confidence interval (CI): 1.91 to 3.51]. In subgroup analyses, female survivors over 65 years had unemployed after treatment (aOR=89.24; 95%CI= 10.52 to 756.91) than at the diagnosis of cancer. Among cancer survivor who remained employed after treatment (n=284), 71.8% found no meaning of working and 15% experienced decrease wages. Conclusions: This is the first study with the largest number of patients investigating employment situation among lung cancer survivors reported poorer employment status than the general population. Among cancer survivors, specifically female survivors over 65 years had greater risk of work loss than general population. These findings should help working people concerned about employment after lung cancer. No significant financial relationships to disclose.
GP is suspended for three months for smacking hand of patient with dementia
Authors: Clare Dyer
Journal: BMJ (2016)

A GP who smacked the hand of a 96 year old woman with dementia and said “don’t you hit me” after she became aggressive has been suspended for three months by a medical practitioners tribunal.

In October 2014 Gary Simpson, 58, visited the 1.4 m tall patient at Stocks Hall Nursing Home near Ormskirk, Lancashire, because of a suspected chest infection. But she was suspicious and hostile, saying that she would hit him.

The tribunal, after hearing evidence from two staff who were present at the incident, found that during the confrontation Simpson pointed in the woman’s face and said “don’t you hit …
Psychiatric residency training: relationships and value development
Authors: Z Taintor, M Morphy, A Seiden, E Val
Journal: American Journal of Psychiatry (1983)

778 Am J Psychiatry 1 40:6, June 1983 The authors review reports from a national sample of third-year residents regarding their reasons for having selected a career in psychiatry, their evaluation of psychiatric training, and the related changes noted in interpersonal relations, social and political attitudes, and personal and professional values. They discuss implications of the data for the specialty. (Am J Psychiatry 140:778-780, 1983)
Genetic Characterization of Waldenstrom Macroglobulinemia By Next Generation Sequencing: An Analysis of Fouteen Genes in a Series of 61 Patients
Authors: Cristina Jimenez, Isabel Prieto-Conde, María García-Álvarez, María Carmen Chillón, Aránzazu García-Mateo, Fernando Escalante, Tomás González-López, Pilar Giraldo, Alfonso Garcia de Coca, Miguel Alcoceba, Ana Balanzategui, Maria Eugenia Sarasquete, Luis Alberto Marin, Maria-Victoria Mateos, Enrique M Ocio, Marcos González, Jesus F San Miguel, Ramon Garcia-Sanz, Noemi Puig
Journal: Blood (2015)
P-158 Radioembolization (SIRT) as a Consolidation Treatment in Colorectal Liver Metastases after First Line Chemotherapy: Efficacy Safety
Authors: E. Cortesi, G. Masi, M. Mancini, S. Caponnetto, F. Urbano, C. Mosillo, S. Scagnoli, E. Notarianni, G. Pelle, C. Vivaldi, A. Falcone, R. Cianni
Journal: Annals of Oncology (2016)
Child psychiatry education for general residents
Authors: J F Greden
Journal: American Journal of Psychiatry (1979)

There is continuing debate about what child psychiatry experiences should be included in a general residency. The author describes the program at the University of Michigan in an effort to provide some insights into the interface between child psychiatry and general residency training. This program is unique in several respects: a 12-month rotation in child psychiatry is offered, and the faculty size and budget of the youth services are comparable to those of the adult services. A survey of all residents and faculty pointed up numerous disagreements as to the length of the rotation and priorities in curriculum. The author discusses the influence of the various competitive processes on the educational program.
Transcription factor TBX4 regulates myofibroblast accumulation and lung fibrosis
Authors: Ting Xie, Jiurong Liang, Ningshan Liu, Caijuan Huan, Yanli Zhang, Weijia Liu, Maya Kumar, Rui Xiao, Jeanine D’Armiento, Daniel Metzger, Pierre Chambon, Virginia E. Papaioannou, Barry R. Stripp, Dianhua Jiang, Paul W. Noble
Journal: Journal of Clinical Investigation (2016)

Progressive tissue fibrosis is a major cause of the morbidity and mortality associated with repeated epithelial injuries and accumulation of myofibroblasts. Successful treatment options are limited by an incomplete understanding of the molecular mechanisms that regulate myofibroblast accumulation. Here, we employed in vivo lineage tracing and real-time gene expression transgenic reporting methods to analyze the early embryonic transcription factor T-box gene 4 (TBX4), and determined that TBX4-lineage mesenchymal progenitors are the predominant source of myofibroblasts in injured adult lung. In a murine model, ablation of TBX4-expressing cells or disruption of TBX4 signaling attenuated lung fibrosis after bleomycin-induced injury. Furthermore, TBX4 regulated hyaluronan synthase 2 production to enable fibroblast invasion of matrix both in murine models and in fibroblasts from patients with severe pulmonary fibrosis. These data identify TBX4 as a mesenchymal transcription factor that drives accumulation of myofibroblasts and the development of lung fibrosis. Targeting TBX4 and downstream factors that regulate fibroblast invasiveness could lead to therapeutic approaches in lung fibrosis.
P-253 Multimodal analgesia combined with epidural anesthesia and intravenous administration of acetaminophen in perioperative management of esophagectomy using modified ERAS protocol
Authors: T. Ogata, T. Nakajima, K. Kano, Y. Maezawa, K. Segami, K. Ikeda, T. Sato, H. Cho, T. Yoshikawa
Journal: Annals of Oncology (2016)
High Risk Multiple Myeloma Cases Are Identified In An MMRC Led Study By The SKY92 Gene Signature (MMprofiler)
Authors: Erik H van Beers, Martin H. Van Vliet, Kenneth C. Anderson, Ajai Chari, Sundar Jagannath, Andrzej Jakubowiak, Shaji K Kumar, Daniel Lebovic, Joan Levy, Sagar Lonial, Donna E Reece, Paul G. Richardson, David S Siegel, Keith Stewart, Suzanne Trudel, Ravi Vij, Todd M. Zimmerman, Rafael Fonseca
Journal: Blood (2013)
Is response classification with PERCIST in stage IV breast cancer influenced by the number of lesions assessed?
Authors: Katja Pinker, Christopher Riedl, Leonard Ong, Maxine S. Jochelson, Gary Ulaner, Maura N. Dickler, Wolfgang Weber
Journal: Journal of Clinical Oncology (2015)

e12004 Background: PERCIST is a framework for the evaluation of tumor response to therapy by 18F-FDG-PET (FDG PET/CT). As primary analysis to quantify tumor response to therapy PERCIST recommends to measure changes in FDG uptake (SUV) of the most FDG-avid lesion. Analysis of the sum of SUVs of up to 5 lesions is suggested as a secondary analysis. The goal of this study was to assess if assessment of the sum of 5 FDG-avid lesions (PERCIST_5) results in a different response classification than assessment of 1 lesion (PERCIST_1). Methods: In this IRB –approved retrospective study the hospital database was searched for patients with stage IV breast cancer, who received first or second line systemic therapy in clinical trials from 2007 to 2012. Sixty-six eligible patients who underwent FDG PET/CT scan at baseline and within 3 months after therapy initiation were identified. Tumor response on FDG PET/CT was correlated with disease specific (DSS) and progression free survival (PFS). Results: In 7 cases, response assessment by PERCIST_1 and PERCIST_5 was discordant (table). All 7 cases were classified as stable disease (SD) by PERCIST_1, but as partial response (n = 6) or progressive disease (n = 1) by PERCIST_5. 2 year-PFS of responders and non-responders was 38.2% and 0% for PERCIST_1 (p < 0.001), and 38.8% and 0% for PERCIST_5 (p < 0.001). Four year-DSS of responders and non-responders was significantly different with 58.5% and 19.9% for PERCIST_1 (p = 0.0036) and 64.3% and 16.8% for PERCIST_5 (p ≤ 0.0001).PERCIST_1 and _5 were not significantly different (p > 0.58). Conclusions: Response assessment classification using an evaluation up to 5 target lesions can decrease the number of patients classified as SD. However, impact on prediction of patient outcome seems limited. PERCIST_1 PERCIST_5 CR PR SD PD Total CR 17 0 0 0 17 PR 0 18 6 0 24 SD 0 0 8 0 8 PD 0 0 1 16 17 Total 17 18 14 17 66